Showing 661 - 680 results of 103,829 for search '(( 5 ((026 decrease) OR (((mean decrease) OR (a decrease)))) ) OR ( 2 fold decrease ))', query time: 1.35s Refine Results
  1. 661

    Nitrile in the Hole: Discovery of a Small Auxiliary Pocket in Neuronal Nitric Oxide Synthase Leading to the Development of Potent and Selective 2‑Aminoquinoline Inhibitors by Maris A. Cinelli (1309419)

    Published 2017
    “…We previously developed a class of membrane-permeable 2-aminoquinoline inhibitors and later rearranged the scaffold to decrease off-target binding. …”
  2. 662
  3. 663

    WT1 siRNA decreases proliferation, pAKT, and Bcl2 expression. by Ayana E. Morales (17756335)

    Published 2024
    “…Corresponding densitometry analysis is noted as protein fold expression compared to GAPDH for WT1, p<0.001(***), vFLIP(ns), LANA p<0.05(*), pAKT p<0.05(*), and BCL2 p <0.05(*) using two-sided, unpaired student t-tests. …”
  4. 664
  5. 665
  6. 666

    Tunicamycin produces a concentration- and time-dependent decrease in cell viability in SH-SY5Y cells concomitant with caspase-3 activation. by Arindam P. Ghosh (317870)

    Published 2013
    “…<p>(A) Treatment of SH-SY5Y cells with tunicamycin (0.1–5µM) for 24 h caused a progressive decrease in cell viability as measured by Calcein AM cleavage assay. …”
  7. 667
  8. 668
  9. 669
  10. 670

    VRK1 overexpression is seen in human breast cancer and is associated with decreased relapse-free survival. by Aye M. Mon (5714912)

    Published 2018
    “…Data for cancer subtypes are shown in boxes numbered 1–11: 1: benign breast neoplasm (rank 6459, 1.4 fold-change, NS), 2: breast carcinoma (rank 833, 1.5 fold-change, p = 3.83x10<sup>-5</sup>), 3: breast phyllodes tumor (rank 512, 1.2 fold-change, p = 0.002), 4: ductal breast carcinoma in situ (rank 1969, 1.5 fold-change, p = 0.002), 5: invasive breast carcinoma (rank 1060, 1.6 fold-change, p = 1.28x10<sup>-5</sup>), 6: invasive ductal and invasive lobular breast carcinoma (rank 941, 1.5 fold-change, p = 6.76x10<sup>-22</sup>), 7: invasive ductal breast carcinoma (rank 613, 1.5-fold change, p = 2.71x10<sup>-71</sup>), 8: invasive lobular breast carcinoma (rank 947, 1.3 fold-change, p = 3.64x10<sup>-28</sup>), 9: medullary breast carcinoma (rank 400, 1.8 fold-change, p = 3.25x10<sup>-12</sup>), 10: mucinous breast carcinoma (rank 1932, 1.4 fold-change, p = 7.41x10<sup>-10</sup>) and 11: tubular breast carcinoma (rank 1253, 1.4 fold-change, p = 1.24x10<sup>-17</sup>). …”
  11. 671
  12. 672

    Signatures of the Protein Folding Pathway in Two-Dimensional Ultraviolet Spectroscopy by Jun Jiang (149215)

    Published 2015
    “…The complexity of signals decreases as the conformational entropy decreases in the course of the folding process. …”
  13. 673

    The novel <i>carboxylesterase 1</i> variant c.662A>G may decrease the bioactivation of oseltamivir in humans by Jaeseong Oh (3947381)

    Published 2017
    “…A novel <i>CES1</i> c.662A>G single nucleotide polymorphism (SNP) was predicted to decrease CES1 enzymatic activity in an <i>in silico</i> analysis. …”
  14. 674
  15. 675
  16. 676
  17. 677

    CC-1<sup>+</sup> immunostained cell numbers decrease by 2 days after TBI and return to control levels by 5 weeks. by Krista A. Dent (709531)

    Published 2015
    “…Panels show contralateral (Contra) and ipsilateral (Ipsi) external capsule (EC) at (A,B) 2 days (2d), (C,D) 2 weeks (2w) and (E,F) 5 weeks (5w) (G) In the external capsule numbers of CC-1<sup>+</sup> oligodendrocytes were decreased by 2d after injury, remained decreased at 2 weeks and returned to normal levels by 5 weeks. …”
  18. 678
  19. 679
  20. 680

    Specific inhibition of ATG5 and ATG7 decrease low glucose-induced LC3-II accumulation. by Delphine Balmer (458897)

    Published 2013
    “…<p>Lentiviruses expressing specific shRNA were used to decrease the expression of ATG5 and ATG7 as described in material & methods, then each clonal cell colony was treated and cultured as mentioned in material & methods. …”